IMMUNE NETWORK

  • 제11권3호
  • /
  • Pages.163-168
  • /
  • 2011
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen

  • 투고 : 2011.05.23
  • 심사 : 2011.06.10
  • 발행 : 2011.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Nanoparticles (NPs) prepared from biodegradable polymers, such as poly (D,L-lactic acid-co-glycolic acid) (PLGA), have been studied as vehicles for the delivery of antigens to phagocytes. This paper describes the preparation of antigen-loaded PLGA-NPs for efficient cross-priming. Methods: NPs containing a similar amount of ovalbumin (OVA) but different sizes were produced using a micromixer-based W/O/W solvent evaporation procedure, and the efficiency of the NPs to induce the cross-presentation of OVA peptides were examined in dendritic cells (DCs). Cellular uptake and biodistribution studies were performed using fluorescein isothiocyanate (FITC)-loaded NPs in mice. Results: The NPs in the range of $1.1{\sim}1.4{\mu}m$ in size were the most and almost equally efficient in inducing the cross-presentation of OVA peptides via $H-2K^b$ molecules. Cellular uptake and biodistribution studies showed that opsonization of the NPs with mouse IgG greatly increased the percentage of FITC-positive cells in the spleen and lymph nodes. The major cell type of FITC-positive cells in the spleen was macrophages, whereas that of lymph nodes was DCs. Conclusion: These results show that IgG-opsonized PLGA-NPs with a mean size of $1.1{\mu}m$ would be the choice of biodegradable carriers for the targeted-delivery of protein antigens for cross-priming in vivo.

키워드

참고문헌

  1. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143;1283-1288, 1976 https://doi.org/10.1084/jem.143.5.1283
  2. Champion JA, Walker A, Mitragotri S: Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 25;1815-1821, 2008 https://doi.org/10.1007/s11095-008-9562-y
  3. Elamanchili P, Diwan M, Cao M, Samuel J: Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22;2406-2412, 2004 https://doi.org/10.1016/j.vaccine.2003.12.032
  4. Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, Han K, Kim K, Lee CK: Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide- co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res 30;1440-1446, 2007 https://doi.org/10.1007/BF02977369
  5. Harding CV, Song R: Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 153;4925-4933, 1994
  6. Heath WR, Carbone FR: Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19;47-64, 2001 https://doi.org/10.1146/annurev.immunol.19.1.47
  7. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264;961-965, 1994 https://doi.org/10.1126/science.7513904
  8. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP: Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57;391-410, 2005 https://doi.org/10.1016/j.addr.2004.09.003
  9. Johansen P, Men Y, Merkle HP, Gander B: Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50;129-146, 2000 https://doi.org/10.1016/S0939-6411(00)00079-5
  10. Karttunen J, Sanderson S, Shastri N: Detection of rare antigen- presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A 89;6020-6024, 1992 https://doi.org/10.1073/pnas.89.13.6020
  11. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J: Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120;18-26, 2007 https://doi.org/10.1016/j.jconrel.2007.03.012
  12. Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, Kim K, Han SS, Lee CK: Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int Immunopharmacol 1;1275-1284, 2001 https://doi.org/10.1016/S1567-5769(01)00052-2
  13. Lee YH, Lee YR, Kim KH, Im SA, Song S, Lee MK, Kim Y, Hong JT, Kim K, Lee CK: Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells. Int Immunopharmacol 2011 [Epub ahead of print]
  14. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han K, Kim K, Eo SK, Lee CK: Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105;3951-3955, 2005 https://doi.org/10.1182/blood-2004-10-3927
  15. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM: Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125;193-209, 2008 https://doi.org/10.1016/j.jconrel.2007.09.013
  16. Newman KD, Sosnowski DL, Kwon GS, Samuel J: Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 87;1421-1427, 1998 https://doi.org/10.1021/js980070s
  17. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55;329-347, 2003 https://doi.org/10.1016/S0169-409X(02)00228-4
  18. Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82;105-114, 2002 https://doi.org/10.1016/S0168-3659(02)00127-X
  19. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ: Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117;78-88, 2006 https://doi.org/10.1111/j.1365-2567.2005.02268.x
  20. Sigal LJ, Crotty S, Andino R, Rock KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398;77-80, 1999 https://doi.org/10.1038/18038
  21. Venkataprasad N, Coombes AG, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM: Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 17;1814-1819, 1999 https://doi.org/10.1016/S0264-410X(98)00372-7
  22. Waeckerle-Men Y, Groettrup M: PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57;475-482, 2005 https://doi.org/10.1016/j.addr.2004.09.007
  23. Yewdell JW, Haeryfar SM: Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 23;651-682, 2005 https://doi.org/10.1146/annurev.immunol.23.021704.115702

피인용 문헌

  1. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation vol.4, pp.7, 2011, https://doi.org/10.2217/imt.12.40
  2. Design strategies for fluorescent biodegradable polymeric biomaterials vol.1, pp.2, 2013, https://doi.org/10.1039/c2tb00071g
  3. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery vol.9, pp.17, 2011, https://doi.org/10.2217/nnm.14.156
  4. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses vol.5, pp.1, 2011, https://doi.org/10.1080/2162402x.2015.1068493
  5. Peptide/protein vaccine delivery system based on PLGA particles vol.12, pp.3, 2011, https://doi.org/10.1080/21645515.2015.1102804
  6. Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy vol.8, pp.None, 2011, https://doi.org/10.3389/fimmu.2017.00879
  7. Co-Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis vol.1, pp.3, 2017, https://doi.org/10.1002/adbi.201700022
  8. Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle vol.35, pp.27, 2011, https://doi.org/10.1016/j.vaccine.2017.05.029
  9. Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens vol.7, pp.None, 2011, https://doi.org/10.1038/s41598-017-13915-x
  10. Enhanced MHC-I antigen presentation from the delivery of ovalbumin by light-facilitated biodegradable poly(ester amide)s nanoparticles vol.6, pp.13, 2011, https://doi.org/10.1039/c7tb03233a
  11. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy vol.48, pp.8, 2011, https://doi.org/10.1080/08820139.2019.1610889
  12. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications vol.34, pp.1, 2011, https://doi.org/10.1038/s41375-019-0540-7
  13. Development of a novel T cell‐oriented vaccine using CTL/Th‐hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium vol.64, pp.10, 2011, https://doi.org/10.1111/1348-0421.12836